# GvHD Prophylaxis in Unrelated Donor HCT: Randomized Trial Comparing PTCY Versus ATG

> **NCT05153226** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **DKMS gemeinnützige GmbH** · enrollment: 640 (actual)

## Conditions studied

- Graft Vs Host Disease
- Peripheral Blood Stem Cell Transplantation
- AML
- MDS
- MDS/MPN
- CMML

## Interventions

- **DRUG:** Cyclophosphamide
- **BIOLOGICAL:** ATG

## Key facts

- **NCT ID:** NCT05153226
- **Lead sponsor:** DKMS gemeinnützige GmbH
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-03-02
- **Primary completion:** 2025-06
- **Final completion:** 2026-12
- **Target enrollment:** 640 (ACTUAL)
- **Last updated:** 2024-12-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05153226

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05153226, "GvHD Prophylaxis in Unrelated Donor HCT: Randomized Trial Comparing PTCY Versus ATG". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05153226. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*